14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BOLD vs SNY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin).
Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both BOLD (36.8/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile SNY trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs SNY. Trailing 12-month operating profitability (BOLD 0.0% vs SNY 22.3%) and valuation multiples (BOLD N/M vs SNY 8.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
SNY Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $110.6B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment52.0% of Rev ($15.6B)
90D Engineering Disclosures0 Published
Investor FAQ BOLD vs SNY Key Questions & Quantitative Answers
As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin). Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both BOLD (36.8/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile SNY trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SNY leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.1B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $30.1B for SNY. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.
SNY screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SNY trades at 8.6x Forward P/E, 22.9x Trailing P/E, 2.90x PEG, and 3.7x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus SNY (5.7% ROE) capital efficiency.
In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 26% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.